This article is more than 5 years old. Information may no longer be current.

Treat-and-extend therapy with Eylea for AMD improves vision, reduces injections over 2 years

Issue: December 25, 2015

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LAS VEGAS — Two-year results of the ATLAS study showed visual and anatomic improvements in eyes with neovascular age-related macular degeneration treated with a treat-and-extend program using Eylea.

“The treat-and-extend program has never been validated with aflibercept [Eylea, Regeneron] to date, and given the molecular differences of anti-VEGF drugs and the potential greater durability effect for aflibercept, my colleagues and I designed and conducted the ATLAS study,“ Carl D. Regillo, MD, FACS, said at the American Academy of Ophthalmology annual meeting.

Carl D. Regillo

Of the 40 patients enrolled in the prospective study, only 18% of subjects had visual acuity (VA) of 20/40 or better. After 1 year, VA improved to 20/40 or better in 48% of patients, and 45% of patients reached the same VA after year 2.

There was an average of 13.9 injections over 2 years: eight in year 1 and 5.9 in year 2.

By the end of the second year, 82% of patients were treated at intervals of 8 weeks or more and more than one-third at 12 weeks or more.

The study also showed a good safety profile.

“These [results] were well-maintained over 2 years of follow-up, and all of this was acknowledged to reduce office visits and injection burden,” Regillo said.

Improvements were very similar to previously published reports using the treat-and-extend approach using ranibizumab and bevacizumab, and also very similar to the fixed regimens using aflibercept, he said. — by Kristie L. Kahl

Reference:

Regillo CD. Prospective, multicenter investigation of aflibercept treat and extend therapy for neovascular age-related macular degeneration (ATLAS study) 2 year results. Presented at: American Academy of Ophthalmology. Nov. 14, 2015; Las Vegas.

Disclosure: Regillo reports he is a consultant for Acucela, Alcon Laboratories, Alimera Sciences, Allergan, Bausch + Lomb, Genentech, NotalVision, Novartis Pharmaceuticals, Pfizer, Regeneron Pharmaceuticals and Thrombogenics; and a speaker for Acucela, Advanced Cell Technology, Alcon Laboratories, Alimera Sciences, Allergan, Genentech, NotalVision, Regeneron Pharmaceuticals, Santen, Second Sight Medical Products and Thrombogenics.